AIM ImmunoTech
13 hedge funds and large institutions have $420K invested in AIM ImmunoTech in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 13 → 13 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
73% less capital invested
Capital invested by funds: $1.53M → $420K (-$1.11M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$19.3K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.3K |
| 3 |
VF
Virtu Financial
New York
|
+$8.77K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$8.77K |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$3.51K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$472K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$462K |
| 3 |
Renaissance Technologies
New York
|
-$7.02K |
| 4 |
Bank of New York Mellon
New York
|
-$5.26K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.75K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $156K | +$12.3K | +7 | +7% |
|
2
BlackRock
New York
| $149K | – | – | – |
|
3
Geode Capital Management
Boston,
Massachusetts
| $24K | – | – | – |
|
|
4
Renaissance Technologies
New York
| $17K | -$7.02K | -4 | -25% |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $16K | +$19.3K | +11 | New |
|
6
Creative Planning
Overland Park,
Kansas
| $13K | – | – | – |
|
7
Northern Trust
Chicago,
Illinois
| $11K | – | – | – |
|
|
GC
8
Guggenheim Capital
Chicago,
Illinois
| $7K | +$3.51K | +2 | +67% |
|
|
VF
9
Virtu Financial
New York
| $7K | +$8.77K | +5 | New |
|
|
10
Wells Fargo
San Francisco,
California
| $6K | +$8.77K | +5 | New |
|
|
11
Bank of New York Mellon
New York
| $5K | -$5.26K | -3 | -50% |
|
|
OAM
12
Occidental Asset Management
Burlingame,
California
| $5K | – | – | – |
|
|
WPW
13
Waldron Private Wealth
Bridgeville,
Pennsylvania
| $3K | – | – | – |
|
|
14
UBS Group
Zurich,
Switzerland
| $1K | -$1.75K | -1 | Closed |
|
|
SM
15
Sabby Management
Miami Beach,
Florida
| – | -$472K | -214 | Closed |
|
|
AFM
16
Anson Funds Management
Dallas,
Texas
| – | -$462K | -210 | Closed |
|
AIM Hedge Fund Activity: Q3 2017 in Review
13 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q3 2017, worth a combined $420K — down 73% from $1.53M a quarter earlier.
Fund positioning in AIM was balanced in Q3 2017: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $19.3K. The largest seller was Sabby Management, exiting entirely with an estimated $472K sold.
- 13 institutional investors held AIM ImmunoTech (AIM) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $420K of AIM ImmunoTech stock for Q3 2017, down 73% quarter-over-quarter.
- 3 funds opened new AIM ImmunoTech positions in Q3 2017 and 3 closed out, a net change of 0 holders.
- The largest AIM ImmunoTech buyer in Q3 2017 was Susquehanna International Group, an estimated $19.3K added.
- The largest AIM ImmunoTech seller in Q3 2017 was Sabby Management, an estimated $472K sold.
Based on aggregated 13F filings for Q3 2017.